<DOC>
	<DOCNO>NCT00887263</DOCNO>
	<brief_summary>The purpose study compare efficacy tolerability budesonide 3 mg effervescent tablet ( 9 mg/day ) compare placebo treatment patient resistant oral cGvHD .</brief_summary>
	<brief_title>Efficacy Safety Study Budesonide Treat Oral Chronic Graft v Host Disease ( cGvHD )</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Karnofsky &gt; = 70 Oral chronic GvHD allogeneic haematopoietic stem cell transplantation Oral cGvHD erosive and/or ulcerative type NIH scale &gt; = 3 Resistant oral cGvHD oral response conventional primary treatment Uncertain diagnosis resistant oral cGvHD Symptomatic oral cGvHD hyperkeratotic type solely Current active oral bacterial , viral , fungal infection Unwilling forego concurrent treatment mucosal lesion and/or related oral pain Requiring addition new systemic therapy include steroid , radiation therapy Local intestinal infection Abnormal hepatic function liver cirrhosis If careful medical monitoring ensure : tuberculosis , cardiovascular disease , diabetes mellitus , osteoporosis , active peptic ulcer disease , glaucoma , cataract , infection Second line treatment oral cGvHD topical steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>